Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks

This article was originally published in The Pink Sheet Daily

Executive Summary

In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.

You may also be interested in...



FDA Hears Mixed Message On Feasibility, Need For Orkambi Vs. Kalydeco Trial

Some experts say a study in CF patients with the 508del mutation could not pass IRB muster, but others see an opportunity to answer the question of whether two drugs are needed or one will suffice.

Return Of Vertex’s Ivacaftor To FDA Panel May Signal Efficacy Concerns

Kalydeco raced to market for cystic fibrosis, but effort to get ‘breakthrough’ approval with lumacaftor for much larger patient population may have FDA worrying about the meaningfulness of pivotal efficacy results.

Novo Nordisk’s Saxenda Initially Positioned For Private Patients In Europe

Obese patients who are severely ill with a high BMI and co-morbidities, and who are highly motivated to try a new therapy and willing to pay for it out-of-pocket, will be targeted for Saxenda.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel